Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.

Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.

Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.